MAPT and Alzheimer disease: This study achieved sensitive detection of key AD biomarkers (including β‐amyloid, Tau, and APP) in both artificial and monkey CSF with detection limits as low as 0.023‐0.098 fm, which was much lower than traditional methods while requiring minimal sample volume.